Stephanie Smith Bewick

Stephanie Smith Bewick has over 20 years of experience in the biotech and pharmaceutical industry, with expertise in business development and strategic planning. Throughout their career, they have held various senior roles in companies such as Accession Therapeutics Limited, Destiny Pharma plc, and Summit Therapeutics plc. As Chief Business Officer at Accession Therapeutics Limited, they are responsible for leading the business development efforts. Prior to that, they served as Chief Business Officer at Destiny Pharma plc, where they played a key role in business development activities. Stephanie also worked as Vice President, Business Development at Summit Therapeutics plc, where they led the out-licensing of product rights and conducted pipeline and acquisition valuations. Stephanie has also worked as an independent biotech business consultant and Senior Director at Apex Healthcare Consulting Ltd. Stephanie holds a strong background in areas such as product forecasting, commercial valuations, market access, and investment analysis. Stephanie's experience spans across various therapeutic areas, including orphan diseases, oncology, and neurology, and they have worked with different product types such as small molecules and biologicals. Overall, Stephanie brings a wealth of knowledge and expertise in business development and strategic planning to their roles in the biotech and pharmaceutical industry.

Stephanie Smith Bewick completed their education in the field of Neuroscience. Stephanie started their educational journey in 1985 at St Andrew's College, Dublin. However, no specific degree or field of study is mentioned for this period. Later, they pursued a Bachelor of Science (BSc Hons) in Neuroscience from The University of Edinburgh, where they studied from 1991 to 1995. After completing their undergraduate degree, Stephanie went on to obtain a Doctor of Philosophy (PhD) in Neuroscience from the University of Bristol between 1995 and 1999.